Innovative Nanobiopharmaceutics

The innovative nanobiopharmaceutics is a socially significant cluster of RUSNANO, which includes 10 enterprises that actually created from scratch their in-house production of both innovative medicines, and generics in one of the fastest growing industries in Russia—pharmaceutical. The main segment of the market of nanomedicine (taking up around 90%) is the application of nanomaterials to create highly effective medicines and vaccines with a good safety profile. The actual production level in this cluster amounted to RUB 4.4 bln in 2017.

  • Selecta Biosciences, Inc. & Selecta RUS
    Selecta Biosciences, Inc. & Selecta RUS

    Development and commercialization of an entirely new class of targeted vaccines that induce antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

    Operating Factories
    from november 2012


  • Pharmsynthez, OJSC
    Pharmsynthez, OJSC

    Pharmsynthez will bring a number of unique and much-needed drugs to Russian and global markets. During this investment phase, clinical trials of the drugs that Pharmsynthez developed will be completed, their large-scale manufacturing will begin, and the drugs will be brought to foreign markets.

    Operating Factories

  • BIND Therapeutics & BIND RUS
    BIND Therapeutics & BIND RUS

    Development and commercialization of a new class of highly selective targeted therapeutics based on BIND Biosciences’s Accurins™ nanoplatform.

    Operating Factories

  • Nearmedic Pharma
    Nearmedic Pharma

    Full-cycle production of innovative nanomedicines via versatile GMP pharmaceutical manufacturer.


    Production of import-substituting innovative pharmaceuticals.

    Operating Factories

  • Panacela Labs, Inc.
    Panacela Labs, Inc.

    Development of the anti-cancer drugs based on the molecular modulators of cellular stress, as well as the treatments against infectious diseases. Currently, company portfolio consists of 5 drug families.

  • Hemacore

    Production of equipment and disposables for evaluating blood-clotting disorders using a new diagnostic method.

    Operating Factories
    from november 2012


  • NTpharma

    GMP production of nanovaccines and biopharmaceuticals containing carbohydrate binders.

  • NBT

    Preparation and packaging of microsources for brachytherapy using isotope 125I. Production of nanostructured microspheres of amorphous material with isotope 90Y.

    Operating Factories


    Production of track membranes with pore diameters of 20 nanometers to 100 nanometers. Production of multifunctional equipment for membrane plasmapheresis, cascade plasma filtration, and other methods of extracorporal hemocorrection.